Alexion Pharmaceuticals Inc., of New Haven, Conn., presented new long-term data from an ongoing, open-label extension of the pivotal phase III ARISE trial of Kanuma (sebelipase alfa) in children and adults with lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease.